Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Conditions
Brief summary
The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA). This was achieved using functional magnetic resonance imaging (fMRI) in conjunction with the point subtraction aggression paradigm (PSAP) Task, a behavioral aggression paradigm in which subjects are provoked by having money indirectly taken from them by a fictitious opponent, simulating an aggression response.
Detailed description
Approximately 30 subjects aged 8-12 diagnosed with ADHD and associated feature of IA were recruited in this study. The PSAP is a behavioral aggression test used to evaluate behavioral response related to impulsive aggression. The task was combined with functional MRI to evaluate the change in brain activity measured as BOLD signal (blood oxygenation level-dependent) from baseline to the end of the treatment with SPN-810. The level of neurotransmitters Glutamate and GABA were also measured using magnetic resonance spectroscopy (MRS). Additionally, the improvement and severity in impulsive aggression behaviors were assessed using validated scales.
Interventions
Neural brain activity measured by fMRI
Glutamate and GABA levels measured by MRS
Aggression score measured by the PSAP task
Treatment of SPN-810 (36 mg) on neuronal brain activity, GABA and Glutamate levels and on the aggression score
Treatment of placebo on neuronal brain activity, GABA and Glutamate levels and on the aggression score
Sponsors
Study design
Intervention model description
A multi-center, double-blind, randomized (1:1), placebo-controlled, parallel-group, 2-arm study
Eligibility
Inclusion criteria
* Otherwise healthy male or female subjects, aged 8-12 years, inclusive, at the time of screening with primary diagnosis of ADHD and currently receiving monotherapy treatment with an optimized US Food and Drug Administration (FDA)-approved ADHD medication. * Impulsive aggression (IA) confirmed at screening using the R-MOAS and the Vitiello Aggression Scale.
Exclusion criteria
* Current or lifetime diagnosis of epilepsy, major depressive disorder, bipolar disorder, schizophrenia or related disorder, personality disorder, Tourette's disorder, fetal alcohol syndrome, or psychosis not otherwise specified. * Currently meeting DSM criteria for autism spectrum disorder, pervasive developmental disorder, obsessive-compulsive disorder, post-traumatic stress disorder. * Known or suspected IQ \<70, pregnancy, substance or alcohol abuse. * Known history of implanted brain stimulator, vagal nerve stimulator, ventriculoperitoneal shunt, cardiac pacemaker, orthodontic braces, or implanted medication port. Visual and hearing (≥25 dB) impairment. * Pre-existing medical or psychological conditions that preclude being in the MRI scanner (e.g., claustrophobia, morbid obesity, or marked anxiety about the procedure).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks. | The primary endpoint was the aggression-related change in the whole brain in BOLD signal fMRI contrast in response to the PSAP task. BOLD fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. Change in brain activity was measured by a change in BOLD response in brain regions during the aggressive response relative to the monetary response, where the aggression was defined as the number of Option 2 presses (aggressive response) divided by the total number of button presses and the number of provocations. Change of aggression-related MRI signal was acquired at baseline and 4 weeks after SPN-810 treatment. A positive number represents an increase in activity. Region of interest is described by the location of the peak value and described by Montreal Neurological Institute (MNI) X, Y, Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Aggressive Response\> Monetary Response. |
| Effect of SPN-810 on the Aggressions Score | Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks. | The Point Subtraction Aggression Paradigm (PSAP) is a behavioral aggression paradigm consisting of a computer game in which each participant plays against a computer to earn points. The subject can steal points (i.e., aggressive behavior) or have points stolen by the opponent (i.e., provocation). The subject can press 1 of 3 buttons on a keypad a set number of times. By pressing the button for Option 1, 100 times, the subject will earn a point; pressing the button for Option 2, 20 consecutive times is the aggression action that results in stealing a point from the opponent; pressing Option 3, 20 times protects the subject from the opponent's attempt to steal points (i.e., money). The aggression score is averaged across two sessions and calculated as the number of Option 2 button presses divided by the sum of total button presses and the number of provocation events received, with a range minimum = 1, maximum = 143. The higher scores reflect increased aggression. |
| Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task | Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks. | BOLD (blood oxygenation level-dependent) fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. It was collected during the PSAP behavioral task while playing the game: the participants play a computer game in which they can steal points (simulating an aggressive behavior) or have points stolen by the opponent (provocation event) by pressing Option 1, 2 or 3 on a keypad a set number of times to achieve a specific outcome. A positive number represents an increase in activity. The region of interest is described by the location of the peak value within that cluster and described by Montreal Neurological Institute (MNI) X, Y, and Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Provocation Event \>Monetary Response. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS) | Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks. | GABA and Glutamate concentrations (mM) were measured in the anterior cingulate cortex using magnetic resonance spectroscopy (MRS). Data represent the change from Baseline (Visit 2) to Visit 5. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) Scale | From Visit 1 (Day -30) to two time points: Visit 4 (Day 21) and Visit 6 (Day 35). | The Clinical Global Impression - Severity of Illness (CGI-S) is a single item clinician rating of clinician's assessment of the severity of IA behaviors. CGI-S was evaluated by the Investigator on a 7- point scale with 1=Normal, 2=Borderline ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Extremely ill. Data represent the change between Baseline (Visit 1/Day -30) and two time points: Visit 4 (Day 21) and Visit 6 (Day 35). |
| Effect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) Score | Visit 1 (Day -30) to Visit 4 (Day 21) and Visit 6 (Day 35). | R-MOAS scale gauges the severity of aggressive behavior: the frequency of the 16 behaviors is rated over the past week in 4 areas (a-d). For each open question in each area, the parent rates the aggressive behaviors on a scale from 0 to 5 or more times. To each area corresponds a weighted category: 1(a), 4(b), 2(c) and 3(d). Therefore, the sum of each area yields a maximum weighted score of 20 (a), 120 (b), 60 (c) and 90 (c). The total score is the sum of the four area scores or 0-290, the higher the score, the more severe the aggressive behavior is. Data represent the change from baseline at each visit. |
| Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) Scale | Visit 4 (Day 21) and Visit 6 (Day 35), for a total of 2 weeks. | The Clinical Global Impression - Improvement Scale (CGI-I) is an assessment of how much the patient's illness has improved or worsened relative to a baseline state at the beginning of treatment. CGI-I was evaluated by the Investigator on a 7-point scale with 1=very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, 7= very much worse. |
Countries
United States
Participant flow
Recruitment details
A multi-center, double-blind, randomized (1:1), placebo-controlled, parallel-group, 2-arm study
Participants by arm
| Arm | Count |
|---|---|
| Placebo Subjects treated with Placebo | 4 |
| High Dose SPN-810 (36 mg) Subjects treated with SPN-810 | 3 |
| Total | 7 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Early Termination | 0 | 1 |
Baseline characteristics
| Characteristic | High Dose SPN-810 (36 mg) | Placebo | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 3 Participants | 4 Participants | 7 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Continuous | 11.3 years STANDARD_DEVIATION 1.15 | 9.5 years STANDARD_DEVIATION 1.29 | 10.3 years STANDARD_DEVIATION 1.5 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 2 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 Participants | 2 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Impulsive Aggression Measured by Clinical Global Impression - Severity Scale (CGI-S) Score | 5.0 units on a scale STANDARD_DEVIATION 1.41 | 5.8 units on a scale STANDARD_DEVIATION 0.96 | 5.5 units on a scale STANDARD_DEVIATION 1.05 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 1 Participants | 2 Participants | 3 Participants |
| Region of Enrollment United States | 3 participants | 4 participants | 7 participants |
| Retrospective-Modified Overt Aggression Scale (R-MOAS) Total Score | 57.0 units on a scale STANDARD_DEVIATION 6 | 102.5 units on a scale STANDARD_DEVIATION 32.3 | 83.0 units on a scale STANDARD_DEVIATION 33.54 |
| Sex: Female, Male Female | 2 Participants | 0 Participants | 2 Participants |
| Sex: Female, Male Male | 1 Participants | 4 Participants | 5 Participants |
| Vitiello Aggression Total Score | -3.7 units on a scale STANDARD_DEVIATION 1.53 | -3.5 units on a scale STANDARD_DEVIATION 1.29 | -3.6 units on a scale STANDARD_DEVIATION 1.27 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 4 | 0 / 3 |
| other Total, other adverse events | 2 / 4 | 1 / 3 |
| serious Total, serious adverse events | 0 / 4 | 0 / 3 |
Outcome results
Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task
The primary endpoint was the aggression-related change in the whole brain in BOLD signal fMRI contrast in response to the PSAP task. BOLD fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. Change in brain activity was measured by a change in BOLD response in brain regions during the aggressive response relative to the monetary response, where the aggression was defined as the number of Option 2 presses (aggressive response) divided by the total number of button presses and the number of provocations. Change of aggression-related MRI signal was acquired at baseline and 4 weeks after SPN-810 treatment. A positive number represents an increase in activity. Region of interest is described by the location of the peak value and described by Montreal Neurological Institute (MNI) X, Y, Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Aggressive Response\> Monetary Response.
Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.
Population: Completed population included all subjects randomized, who had a Baseline imaging scan (including the anatomical scan) and post-treatment imaging scans.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| SPN-810 (36 mg) > Placebo | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Left Cuneus: Montreal Neurological Institute coordinates -23.5, 96.5, 5.5 | 145 Voxels |
| SPN-810 (36 mg) > Placebo | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Superior Medial Frontal Gyrus: Montreal Neurological Institute coordinates 2.5, -47.5, 39.5 | 0 Voxels |
| SPN-810 (36 mg) > Placebo | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Inferior Occipital Gyrus/Cerebellum: Montreal Neurological Institute coordinates -29.5, 62.5, -4.5 | 353 Voxels |
| SPN-810 (36 mg) > Placebo | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Right Cerebellum: Montreal Neurological Institute coordinates: -35.5, 72.5, -40.5 | 0 Voxels |
| SPN-810 (36 mg) > Placebo | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Right Middle Occipital Gyrus: Montreal Neurological Institute coordinates -1.5, 64.5, 57.5 | 133 Voxels |
| SPN-810 (36 mg) > Placebo | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Right Superior/Middle Frontal Gyrus: Montreal Neurological Institute coordinates -37.5, -33.5, 33.5 | 0 Voxels |
| SPN-810 (36 mg) > Placebo | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Left Angular Gyrus (WM): Montreal Neurological Institute coordinates 4.5, 84.5, 35.5 | 173 Voxels |
| SPN-810 (36 mg) > Placebo | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Right Insula Montreal Neurological Institute coordinates -39.5, -13.5, -0.5 | 0 Voxels |
| SPN-810 (36 mg) > Placebo | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Medial Precuneus: Montreal Neurological Institute coordinates -33.5, 34.5, 47.5 | 128 Voxels |
| SPN-810 (36 mg) > Placebo | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Right Inferior Temporal Gyrus: Montreal Neurological Institute coordinates -41.5, -7.5, -46.5 | 0 Voxels |
| SPN-810 (36 mg) > Placebo | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Right Fusiform Gyrus/Inferior Occipital Cortex: Montreal Neurological Institute 32.5, 52.5, 23.5 | 258 Voxels |
| SPN-810 (36 mg) > Placebo | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Left Postcentral Gyrus: Montreal Neurological Institute coordinates 30.5, 30.5, 51.5 | 0 Voxels |
| SPN-810 (36 mg) > Placebo | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Right Postcentral Gyrus: Montreal Neurological Institute coordinates -29.5, 62.5, -4.5 | 110 Voxels |
| Placebo > SPN-810 (36 mg) | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Left Postcentral Gyrus: Montreal Neurological Institute coordinates 30.5, 30.5, 51.5 | 110 Voxels |
| Placebo > SPN-810 (36 mg) | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Inferior Occipital Gyrus/Cerebellum: Montreal Neurological Institute coordinates -29.5, 62.5, -4.5 | 0 Voxels |
| Placebo > SPN-810 (36 mg) | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Right Fusiform Gyrus/Inferior Occipital Cortex: Montreal Neurological Institute 32.5, 52.5, 23.5 | 0 Voxels |
| Placebo > SPN-810 (36 mg) | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Left Angular Gyrus (WM): Montreal Neurological Institute coordinates 4.5, 84.5, 35.5 | 0 Voxels |
| Placebo > SPN-810 (36 mg) | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Left Cuneus: Montreal Neurological Institute coordinates -23.5, 96.5, 5.5 | 0 Voxels |
| Placebo > SPN-810 (36 mg) | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Right Middle Occipital Gyrus: Montreal Neurological Institute coordinates -1.5, 64.5, 57.5 | 0 Voxels |
| Placebo > SPN-810 (36 mg) | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Medial Precuneus: Montreal Neurological Institute coordinates -33.5, 34.5, 47.5 | 0 Voxels |
| Placebo > SPN-810 (36 mg) | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Right Postcentral Gyrus: Montreal Neurological Institute coordinates -29.5, 62.5, -4.5 | 0 Voxels |
| Placebo > SPN-810 (36 mg) | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Superior Medial Frontal Gyrus: Montreal Neurological Institute coordinates 2.5, -47.5, 39.5 | 329 Voxels |
| Placebo > SPN-810 (36 mg) | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Right Cerebellum: Montreal Neurological Institute coordinates: -35.5, 72.5, -40.5 | 175 Voxels |
| Placebo > SPN-810 (36 mg) | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Right Superior/Middle Frontal Gyrus: Montreal Neurological Institute coordinates -37.5, -33.5, 33.5 | 164 Voxels |
| Placebo > SPN-810 (36 mg) | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Right Insula Montreal Neurological Institute coordinates -39.5, -13.5, -0.5 | 140 Voxels |
| Placebo > SPN-810 (36 mg) | Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task | Right Inferior Temporal Gyrus: Montreal Neurological Institute coordinates -41.5, -7.5, -46.5 | 145 Voxels |
Effect of SPN-810 on the Aggressions Score
The Point Subtraction Aggression Paradigm (PSAP) is a behavioral aggression paradigm consisting of a computer game in which each participant plays against a computer to earn points. The subject can steal points (i.e., aggressive behavior) or have points stolen by the opponent (i.e., provocation). The subject can press 1 of 3 buttons on a keypad a set number of times. By pressing the button for Option 1, 100 times, the subject will earn a point; pressing the button for Option 2, 20 consecutive times is the aggression action that results in stealing a point from the opponent; pressing Option 3, 20 times protects the subject from the opponent's attempt to steal points (i.e., money). The aggression score is averaged across two sessions and calculated as the number of Option 2 button presses divided by the sum of total button presses and the number of provocation events received, with a range minimum = 1, maximum = 143. The higher scores reflect increased aggression.
Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.
Population: Completed population included all subjects randomized, who had a Baseline imaging scan (including the anatomical scan) and post-treatment imaging scans.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SPN-810 (36 mg) > Placebo | Effect of SPN-810 on the Aggressions Score | Baseline/Visit 2 | 8.43 score on a scale | Standard Deviation 9.22 |
| SPN-810 (36 mg) > Placebo | Effect of SPN-810 on the Aggressions Score | Visit 5 | 9.26 score on a scale | Standard Deviation 5.5 |
| Placebo > SPN-810 (36 mg) | Effect of SPN-810 on the Aggressions Score | Baseline/Visit 2 | 10.23 score on a scale | Standard Deviation 6.21 |
| Placebo > SPN-810 (36 mg) | Effect of SPN-810 on the Aggressions Score | Visit 5 | 4.02 score on a scale | Standard Deviation 2.6 |
Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task
BOLD (blood oxygenation level-dependent) fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. It was collected during the PSAP behavioral task while playing the game: the participants play a computer game in which they can steal points (simulating an aggressive behavior) or have points stolen by the opponent (provocation event) by pressing Option 1, 2 or 3 on a keypad a set number of times to achieve a specific outcome. A positive number represents an increase in activity. The region of interest is described by the location of the peak value within that cluster and described by Montreal Neurological Institute (MNI) X, Y, and Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Provocation Event \>Monetary Response.
Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.
Population: Completed population included all subjects randomized, who had a Baseline imaging scan (including the anatomical scan) and post-treatment imaging scans.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| SPN-810 (36 mg) > Placebo | Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task | Left Middle/Inferior Temporal Gyrus: Montreal Neurological Institute coordinates 52.5, 16.5, -24.5 | 137 Voxels |
| SPN-810 (36 mg) > Placebo | Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task | Left Inferior Frontal Gyrus: Montreal Neurological Institute coordinates: 42.5, -15.5, 19.5 | 0 Voxels |
| SPN-810 (36 mg) > Placebo | Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task | Medial Cerebellum: Montreal Neurological Institute coordinates: 12.5, 50.5 -32.5 | 0 Voxels |
| SPN-810 (36 mg) > Placebo | Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task | Right Cerebellum: Montreal Neurological Institute coordinates: -23.5, 70.5, -24.5 | 0 Voxels |
| SPN-810 (36 mg) > Placebo | Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task | Right Postcentral Gyrus: Montreal Neurological Institute coordinates: -31.5, 30.5, 43.5 | 318 Voxels |
| Placebo > SPN-810 (36 mg) | Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task | Right Cerebellum: Montreal Neurological Institute coordinates: -23.5, 70.5, -24.5 | 109 Voxels |
| Placebo > SPN-810 (36 mg) | Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task | Right Postcentral Gyrus: Montreal Neurological Institute coordinates: -31.5, 30.5, 43.5 | 0 Voxels |
| Placebo > SPN-810 (36 mg) | Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task | Left Middle/Inferior Temporal Gyrus: Montreal Neurological Institute coordinates 52.5, 16.5, -24.5 | 0 Voxels |
| Placebo > SPN-810 (36 mg) | Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task | Medial Cerebellum: Montreal Neurological Institute coordinates: 12.5, 50.5 -32.5 | 123 Voxels |
| Placebo > SPN-810 (36 mg) | Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task | Left Inferior Frontal Gyrus: Montreal Neurological Institute coordinates: 42.5, -15.5, 19.5 | 122 Voxels |
Effect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS)
GABA and Glutamate concentrations (mM) were measured in the anterior cingulate cortex using magnetic resonance spectroscopy (MRS). Data represent the change from Baseline (Visit 2) to Visit 5.
Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.
Population: Completed population included all subjects randomized, who had a Baseline imaging scan (including the anatomical scan) and post-treatment imaging scans
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SPN-810 (36 mg) > Placebo | Effect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS) | GABA (mM) | 0.79 mM | Standard Deviation 0.26 |
| SPN-810 (36 mg) > Placebo | Effect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS) | Glutamate (mM) | 0.78 mM | Standard Deviation 2.44 |
| Placebo > SPN-810 (36 mg) | Effect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS) | GABA (mM) | 0.75 mM | Standard Deviation 0.67 |
| Placebo > SPN-810 (36 mg) | Effect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS) | Glutamate (mM) | 0.23 mM | Standard Deviation 1.91 |
Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) Scale
The Clinical Global Impression - Improvement Scale (CGI-I) is an assessment of how much the patient's illness has improved or worsened relative to a baseline state at the beginning of treatment. CGI-I was evaluated by the Investigator on a 7-point scale with 1=very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, 7= very much worse.
Time frame: Visit 4 (Day 21) and Visit 6 (Day 35), for a total of 2 weeks.
Population: Completed population included all subjects randomized, who had a Baseline imaging scan (including the anatomical scan) and post-treatment imaging scans.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SPN-810 (36 mg) > Placebo | Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) Scale | Visit 4 | 2.3 score on a scale | Standard Deviation 1.26 |
| SPN-810 (36 mg) > Placebo | Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) Scale | Visit 6 | 2.3 score on a scale | Standard Deviation 1.26 |
| Placebo > SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) Scale | Visit 4 | 1.5 score on a scale | Standard Deviation 0.71 |
| Placebo > SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) Scale | Visit 6 | 1.0 score on a scale | Standard Deviation 0 |
Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) Scale
The Clinical Global Impression - Severity of Illness (CGI-S) is a single item clinician rating of clinician's assessment of the severity of IA behaviors. CGI-S was evaluated by the Investigator on a 7- point scale with 1=Normal, 2=Borderline ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Extremely ill. Data represent the change between Baseline (Visit 1/Day -30) and two time points: Visit 4 (Day 21) and Visit 6 (Day 35).
Time frame: From Visit 1 (Day -30) to two time points: Visit 4 (Day 21) and Visit 6 (Day 35).
Population: Completed population included all subjects randomized, who had a Baseline imaging scan (including the anatomical scan) and post-treatment imaging scans.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SPN-810 (36 mg) > Placebo | Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) Scale | Visit 4 | -1.25 score on a scale | Standard Deviation 1.5 |
| SPN-810 (36 mg) > Placebo | Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) Scale | Visit 6 | -2.25 score on a scale | Standard Deviation 1.5 |
| Placebo > SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) Scale | Visit 4 | -1.5 score on a scale | Standard Deviation 2.12 |
| Placebo > SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) Scale | Visit 6 | -1.5 score on a scale | Standard Deviation 2.12 |
Effect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) Score
R-MOAS scale gauges the severity of aggressive behavior: the frequency of the 16 behaviors is rated over the past week in 4 areas (a-d). For each open question in each area, the parent rates the aggressive behaviors on a scale from 0 to 5 or more times. To each area corresponds a weighted category: 1(a), 4(b), 2(c) and 3(d). Therefore, the sum of each area yields a maximum weighted score of 20 (a), 120 (b), 60 (c) and 90 (c). The total score is the sum of the four area scores or 0-290, the higher the score, the more severe the aggressive behavior is. Data represent the change from baseline at each visit.
Time frame: Visit 1 (Day -30) to Visit 4 (Day 21) and Visit 6 (Day 35).
Population: Completed population included all subjects randomized, who had a Baseline imaging scan (including the anatomical scan) and post-treatment imaging scans.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SPN-810 (36 mg) > Placebo | Effect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) Score | Visit 4 | -52.0 score on a scale | Standard Deviation 30.23 |
| SPN-810 (36 mg) > Placebo | Effect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) Score | Visit 6 | -61.0 score on a scale | Standard Deviation 18.81 |
| Placebo > SPN-810 (36 mg) | Effect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) Score | Visit 4 | -43.0 score on a scale | Standard Deviation 2.83 |
| Placebo > SPN-810 (36 mg) | Effect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) Score | Visit 6 | -39.5 score on a scale | Standard Deviation 24.75 |